.jpeg)
2026-08-06 07:11:28
Phase 3 FIGHT-302 data presented at the 2026 ASCO Annual Meeting demonstrate that pemigatinib (Pemazyre) as first-line monotherapy significantly prolongs progression-free survival versus gemcitabine plus cisplatin in patients with FGFR2-rearranged unresectable cholangiocarcinoma, establishing a new precision-targeted standard for this molecularly defined population.
2026-08-06 06:54:38
Selpercatinib (Retevmo) is the first approved highly selective RET kinase inhibitor, dosed twice daily at 120 mg or 160 mg based on body weight, indicated for RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer, and other RET-altered malignancies.
2026-08-06 06:49:15
Mitotane is the cornerstone drug for adrenocortical carcinoma treatment, yet its side-effect profile extends well beyond common gastrointestinal discomfort to include adrenal insufficiency, neurological effects, and hepatic changes, necessitating systematic monitoring and proactive clinical management.
2026-08-06 06:43:18
Ponatinib is a third-generation tyrosine kinase inhibitor designed to target the BCR::ABL1 oncoprotein, offering a precision therapy option for Philadelphia chromosome-positive leukemias, particularly in patients harboring the T315I mutation or exhibiting resistance to prior TKIs.
2026-08-05 03:49:14
Axitinib is a highly selective oral VEGFR tyrosine kinase inhibitor approved for advanced renal cell carcinoma (RCC) as first-line combination therapy and second-line monotherapy. This article reviews its indications, composition, mechanism of action, critical pre-treatment warnings, and drug interactions to support safe clinical use.
2026-08-05 03:41:49
Cabergoline is a long-acting dopamine D2 receptor agonist and a first-line treatment for hyperprolactinemia. This article explains its pharmacological mechanism and highlights four critical warnings—cardiac valve disease, orthostatic hypotension, neuropsychiatric effects, and pregnancy/lactation—along with contraindications and standard dosing.
2026-08-05 03:34:24
Capmatinib (Tabrecta) is the first highly selective MET inhibitor approved for MET exon 14 skipping mutation-positive non-small cell lung cancer (NSCLC). This article covers the purchasing channels, reliability assessment, efficacy data, version differences, and safety monitoring tips for the Laos generic version, helping patients make informed treatment decisions.
2026-08-04 03:43:45
Eltrombopag olamine is a key oral thrombopoietin receptor agonist (TPO-RA) used in the treatment of immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). This guide details the correct administration timing requirements, alternative options when the originator product is unavailable, switching precautions, and safety monitoring to support standardized patient care.
2026-08-04 03:22:38
Osimertinib is a cornerstone targeted therapy for EGFR mutation-positive non-small cell lung cancer (NSCLC). This comprehensive guide covers its composition, mechanism of action, critical food interactions (three fruits and vegetables to avoid), pre-treatment assessments, and drug interaction management to ensure safe and effective use.
2026-08-04 03:16:47
Avatrombopag is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) widely used in the management of chronic liver disease-associated thrombocytopenia and immune thrombocytopenia (ITP). This article provides a comprehensive overview of its composition, mechanism of action, indications, precise medication criteria, and adverse reaction management.
2026-08-03 05:08:22
A comprehensive overview of the standard dosing regimen for the EZH2 inhibitor tazemetostat, bioequivalence of the Laos generic formulation, cross-comparison with alternative therapies, and critical safety guidance following the global market withdrawal.
2026-07-31 05:29:27
Tivozanib (brand name FOTIVDA) is an oral, highly selective VEGFR tyrosine kinase inhibitor primarily indicated for patients with advanced renal cell carcinoma who have progressed after multiple prior systemic therapies, representing a key advancement in precision-targeted kidney cancer treatment.
